Avantax Advisory Services Inc. Buys New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Avantax Advisory Services Inc. acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 2,140 shares of the specialty pharmaceutical company’s stock, valued at approximately $264,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $25,000. Jones Financial Companies Lllp grew its stake in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after buying an additional 130 shares during the last quarter. UMB Bank n.a. grew its position in Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares during the last quarter. Lindbrook Capital LLC increased its holdings in shares of Jazz Pharmaceuticals by 82.6% during the fourth quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 176 shares during the period. Finally, Itau Unibanco Holding S.A. raised its stake in shares of Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 172 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Down 4.8 %

Jazz Pharmaceuticals stock opened at $135.25 on Wednesday. The company has a market capitalization of $8.21 billion, a price-to-earnings ratio of 19.05, a PEG ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company’s fifty day moving average price is $132.04 and its two-hundred day moving average price is $122.23. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06.

Insider Activity

In other news, CAO Patricia Carr sold 1,140 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at approximately $966,323.72. The trade was a 13.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CMO Robert Iannone sold 2,403 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $138.41, for a total value of $332,599.23. Following the completion of the transaction, the chief marketing officer now owns 79,621 shares of the company’s stock, valued at $11,020,342.61. The trade was a 2.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock valued at $4,022,825 over the last 90 days. 4.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

JAZZ has been the topic of several research analyst reports. Morgan Stanley reissued an “overweight” rating and set a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Needham & Company LLC restated a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Truist Financial boosted their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Finally, HC Wainwright increased their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.